← Back to catalogue

TrueBeam, TrueBeam STX, Edge and VitalBeam

FDA 510(k)EUDAMED

Class II (US FDA 510(k))

510(k) K252948

by Varian Medical Systems, Inc.

Identifiers

510(k) Number
K252948 FDA 510(k)
FDA Product Code
IYE FDA 510(k)

Classification

Device Class
Class II FDA 510(k)
Legislation / Framework
21 CFR Part 892.5050 FDA 510(k)
Regulation Number
892.5050 FDA 510(k)
Advisory Committee
Radiology FDA 510(k)
FDA Decision
SESE Substantially Equivalent FDA 510(k)

The TrueBeam, TrueBeam STX, Edge, and VitalBeam are linear accelerators designed for external beam radiotherapy. These devices deliver precise, high-energy photon and electron beams to treat malignant and benign conditions, including cancers and non-cancerous tumors, through advanced radiation therapy techniques such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiation therapy (SBRT).

These systems are intended for use in radiation oncology departments within hospitals or specialized cancer centers. They are non-sterile, reusable medical devices classified as Class II under FDA regulations and comply with the Medical Device Regulation (MDR). Each model—TrueBeam, TrueBeam STX, Edge, and VitalBeam—may vary in configuration and capabilities but share core functionality for radiation delivery. Authorized under FDA 510(k) clearance and MDR compliance, they are regulated under the FDA’s 510(k) pathway and the EU’s MDR framework.

This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them.

Authorization Coverage (2 countries)

Regulatory Authorizations

European Union Active

MDR

United States Active

FDA_510K

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (2)

  • FDA 510(k) K252948 24 fields · synced Oct 6, 2026
  • EUDAMED 1 fields · synced May 19, 2026